Article
Clinical Neurology
Tomiki Sumiyoshi, Tatsuya Hoshino, Izumi Mishiro, Lene Hammer-Helmich, Holly Ge, Yoshiya Moriguchi, Keita Fujikawa, Jovelle L. Fernandez
Summary: Early improvement in depressive symptoms predicts better cognitive outcomes in patients with Major Depressive Disorder (MDD). Grouping patients by mood and cognition status in early stages of antidepressant treatments may help improve long-term functional outcomes.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Engineering, Biomedical
Yueheng Peng, Yang Huang, Baodan Chen, Mengling He, Lin Jiang, Yuqin Li, Xunan Huang, Changfu Pei, Shu Zhang, Cunbo Li, Xiabing Zhang, Tao Zhang, Yutong Zheng, Dezhong Yao, Fali Li, Peng Xu
Summary: This study analyzed resting-state electroencephalogram (EEG) data from patients with major depressive disorder (MDD) and found that the corresponding EEG networks weakened significantly after short-term antidepressant treatment. This change in network properties within one week of medication reliably predicted the eventual medication efficacy. Additionally, the baseline EEG networks accurately distinguished responders from non-responders with a high accuracy.
IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING
(2022)
Article
Clinical Neurology
Gernot Fugger, Lucie Bartova, Chiara Fabbri, Giuseppe Fanelli, Raffaella Zanardi, Markus Dold, Alexander Kautzky, Dan Rujescu, Daniel Souery, Julien Mendlewicz, Joseph Zohar, Stuart Montgomery, Alessandro Serretti, Siegfried Kasper
Summary: A study found that European patients who were prescribed NaSSAs as first-line antidepressant treatment had characteristics such as older age, male gender, unemployment, additional melancholic and catatonic features, inpatient treatment, lower dosages of antidepressants but higher rates of augmentation with low-potency antipsychotics, and greater reductions of depressive symptoms during their current major depressive episodes.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Public, Environmental & Occupational Health
Aya Ahmed Abousheishaa, Nor Hazila Mat Lazim, Song Ling Tang, Ahmad Hatim Sulaiman, Hasniza Zaman Huri, Ng Chong Guan
Summary: This study developed and evaluated a decision aid tool for Malaysian patients with MDD to support treatment decision-making during consultation. The tool increased patients' involvement in shared decision making and enhanced their preparedness for decision making without extending the consultation time.
PATIENT EDUCATION AND COUNSELING
(2022)
Article
Psychiatry
Jeffrey R. Strawn, Jeffrey A. Mills, Vikram Suresh, Taryn Mayes, Melanie T. Gentry, Madhukar Trivedi, Paul E. Croarkin
Summary: Understanding how age affects antidepressant response is important for treatment selection. This study analyzed participant-level data from NIH-sponsored trials to identify the impact of age on antidepressant response.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Article
Psychiatry
Robert Gyorgy Vida, Eszter Saghy, Richard Bella, Sandor Kovacs, Dalma Erdosi, Judit Jozwiak-Hagymasy, Antal Zemplenyi, Tamas Tenyi, Peter Osvath, Viktor Voros
Summary: A systematic literature review found that unilateral High-Frequency Left-sided (HFL) repetitive Transcranial Magnetic Stimulation (rTMS) was more effective than sham rTMS in treating Treatment-Resistant Depression (TRD). rTMS may be beneficial as an adjunctive treatment in patients with Major Depressive Disorder (MDD) after two treatment failures.
Article
Psychology, Clinical
Ole Kohler-Forsberg, Louisa G. Sylvia, Vicki Fung, Lindsay Overhage, Michael Thase, Joseph R. Calabrese, Thilo Deckersbach, Mauricio Tohen, Charles L. Bowden, Melvin McInnis, James H. Kocsis, Edward S. Friedman, Terence A. Ketter, Susan L. McElroy, Richard C. Shelton, Michael J. Ostacher, Dan V. Iosifescu, Andrew A. Nierenberg
Summary: In this study, adjunctive antidepressant treatment was not associated with lower depressive symptoms or higher mania symptoms in outpatients with bipolar disorder. There were no differences in treatment effects on mania scales, and potential biases due to nonrandomized design complicated causal interpretations, with no evidence suggesting better treatment effects of adjunctive antidepressants.
DEPRESSION AND ANXIETY
(2021)
Article
Psychiatry
Gary S. Sachs, Paul P. Yeung, Ludmyla Rekeda, Arifulla Khan, Julie L. Adams, Maurizio Fava
Summary: This study aimed to investigate the efficacy of cariprazine as adjunctive therapy for patients with major depressive disorder and nonresponse to at least one antidepressant monotherapy. The results showed that cariprazine significantly reduced depressive symptoms with minimal adverse effects.
AMERICAN JOURNAL OF PSYCHIATRY
(2023)
Review
Medicine, General & Internal
Anna Mosiolek, Aleksandra Pieta, Slawomir Jakima, Natalia Zborowska, Jadwiga Mosiolek, Agata Szulc
Summary: Major depressive disorder is a prevalent mental illness worldwide, with more than 30% of patients not achieving remission through conventional therapy. Inflammation and disturbed neurogenesis are implicated in the pathophysiology of depression, with potential involvement of neurotrophic factors in patient recovery. The influence of antidepressants on inflammatory cytokines and neurotrophins remains inconsistent, with selective serotonin reuptake inhibitors, selective serotonin and noradrenaline inhibitors, and tricyclic antidepressants showing possible anti-inflammatory properties. Further research is needed to determine the role of inflammatory markers in predicting treatment response in MDD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Pawel Mocko, Katarzyna Sladowska, Pawel Kawalec, Yana Babii, Andrzej Pilc
Summary: Major depressive disorder is a severe mental disorder that can lead to suicide if left untreated. Scopolamine is being explored as a potential therapeutic option for depression, with varying levels of antidepressant effects observed in studies. Further large randomized controlled trials are needed to confirm the effectiveness and safety of scopolamine in treating depression, particularly through different routes of administration.
Article
Chemistry, Physical
Vaibhav Mehra, Niloy Sarkar, Bibhu Biswal, Mahima Kaushik
Summary: Depression affects a significant portion of the adult population, but common antidepressants are not universally effective. A proposed solution involves using nanocarriers for targeted drug delivery of an antidepressant. In silico simulations showed that nanocarriers can release the drug in different neuronal environments, providing a potential strategy for improved antidepressant therapy. Further in vivo experimentation is needed to validate these findings and develop an optimized nanoformulation for antidepressant delivery.
MOLECULAR SIMULATION
(2023)
Article
Clinical Neurology
Saba Hoobehfekr, Hossein Sanjari Moghaddam, Mohammadreza Shalbafan, Maryam Ghazizadeh Hashemi, Mohammad Mehdi Pirmoradi, Amirhossein Sakenian, Amirhossein Poopak, Shayan Kashefinejad, Masoomeh Yarahmadi, Shahin Akhondzadeh
Summary: Combination therapy of tipepidine with citalopram can effectively improve symptoms of patients with major depressive disorder in a shorter period of treatment, with higher rates of remission and response. There was no significant difference between the two groups in baseline parameters or frequency of side-effects. Further studies with larger sample sizes and longer follow-up treatment are needed to confirm these findings.
PSYCHIATRY AND CLINICAL NEUROSCIENCES
(2021)
Article
Psychiatry
Qi Zhou, Xiaozhen Lv, Shuzhe Zhou, Qi Liu, Hongjun Tian, Kerang Zhang, Jing Wei, Gang Wang, Qiaoling Chen, Gang Zhu, Xueyi Wang, Cuixia An, Nan Zhang, Yu Huang, Tianmei Si, Xin Yu, Chuan Shi
Summary: Inflammation and cognition are related to major depressive disorder (MDD). Treatment response in MDD patients is associated with different cognitive defects, especially in speed of processing and executive function. Factors such as smoking, alcohol drinking, baseline cognitive performance, and cytokine levels may influence treatment response.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Yi-Hsien Chen, Wei-Ming Wang, I-Hsun Li, Hui-Han Kao, Chin-Bin Yeh, Li-Ting Kao
Summary: The study provides evidence that MDD is an independent risk factor for developing psoriasis, with a higher risk in males. Further investigation is needed to explore the underlying pathological mechanisms in the psychiatric field.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Huifeng Zhang, Zhiguo Wu, Lan Cao, Yousong Su, Fan Wang, Wu Hong, Yiyun Cai, Daihui Peng, Yiru Fang
Summary: Despite numerous treatment options for major depressive disorder (MDD), the efficacy of treatment remains uncertain. Algorithm-guided treatments (AGTs) are proposed to address this issue. This study evaluated the clinical benefit of AGTs for MDD and identified specific moderators that influence treatment outcomes. AGTs were found to have advantages in quality of life and relapse rates compared to treatment-as-usual (TAU), with disease episode types and somatic symptoms playing a significant role in treatment outcomes.
JOURNAL OF AFFECTIVE DISORDERS
(2022)